ERBB2 and breast carcinoma: Data of one clinical trial suggest that an addition of paclitaxel to anthracycline (an antibiotic class of chemotherapy that is cell-cycle non-specific) was only beneficial for women who had an overexpression of the human epidermal growth factor receptor 2 (HER2) in tumors of early breast cancer [57].